Physician profile
Jay S Adams
NPI 1518923424
$1,651.08
in general payments reported to CMS, 2019-2025
22 companies · $43.67 in 2025
The $43.67 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $110 · 2021: $84.03 · 2022: $362 · 2023: $406 · 2024: $123 · 2025: $43.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.34 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $184.74 | 2019-2023 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $153.40 | 2019-2024 | Dupixent, Libtayo |
| Amgen INC. | $136.12 | 2019-2023 | Otezla |
| Leo Pharma INC. | $133.13 | 2021-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $124.68 | 2019-2025 | |
| Genentech USA, INC. | $119.88 | 2019 | |
| Janssen Biotech, INC. | $75.59 | 2020-2023 | Tremfya |
| Genzyme Corporation | $47.13 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $42.25 | 2020-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2022-2024 | Sotyktu |
| Dusa Pharmaceuticals, INC. | $37.85 | 2019 | |
| Mayne Pharma Commercial LLC | $36.41 | 2019 | |
| Pfizer INC. | $35.18 | 2019-2023 | |
| Ucb, INC. | $34.29 | 2019-2023 | Cimzia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $28.28 | 2021-2022 | |
| Organogenesis INC. | $23.63 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.72 | 2019 | |
| Stemline Therapeutics INC. | $15.29 | 2019 | |
| Arcutis Biotherapeutics, INC. | $12.71 | 2023 | |
| Almirall LLC | $12.09 | 2019 | |
| Biofrontera INC. | $1.37 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.